A start-up pharma company based in the UK has a relationship with investors interested in backing a pharma acquisition anywhere in Europe with min EUR 15M in sales (not declining) and positive EBITDA. The company does not have operations in European pharma industry yet, but its management is looking for suiting a company, with owners willing to exit their company to an experienced management team backed up by PE.
The buyer is a is a start-up with no operations or employees at present. However, the company has been in touch with large pharma investors who want to seek out assets in the prescription pharma industry, available for acquisition.
The manager of the buyer is a professional in the pharma industry, with a long track record in pharma M&A (banking and industry). The manager has experience, has already led a large acquisition in Europe and has worked on a number of other acquisitions and divestitures.
The other members of the management team will come from consultants (Regulatory, Supply Chain, Finance) and other team members will be identified in later stages (commercial operations, most likely Market Access, Medical Affairs, Marketing). The investors also have experience with successful M&A projects across Europe.
The buyer wants to use the acquired company as a starting point for larger operations in pharma, and more acquisition may take place after the first one.
Contact us to get details about this prescription pharma company in Europe buyer
This buyer is scanning the market for a pharma prescription company – ideally a hospital or specialty physician customer target group. The buyer is not focused on any specific therapeutic area; however, the preference is for hospital medicines business (prescription drugs).
The company is looking mainly for distributors, they are not interested in manufacturing facilities.
The target company should not be in significant debt and have stable positive EBITDA levels. The revenue should have a growing trend, should not be in decline. Companies with revenues exceeding EUR 15M in recent years will suit the buyer. The EBITDA target is 2M EUR and more. In the case of smaller EBITDA levels, there should be a way to increase this, either through cost-cutting on increasing sales. Not having declining cash flows is a key condition so a business which is in decline will not be of interest.
The acquisition could potentially be the starting point for the buyer’s operations in Europe. The buyer is interested in targets all over Europe.
Feel free to contact us for more information regarding this pharma prescription company wanted in Europe, or if you know possible interested or suited parties. For more buyers of pharmaceutical companies, please visit the section pharmaceutical companies wanted. For pharmaceutical companies for sale visit the section pharmaceutical companies for sale.
Note: CFIE only works with formal companies. We do get a lot of requests and it is difficult to follow up on all inquiries from visitors to our website. For each company, we assess the likelihood of a future transaction. We only get back to you if we see a realistic opportunity to do a future acquisition or business sale. In order to increase your chances of receiving a reply as an individual, please explain as much as possible about your personal background, strategy and fit with the target. There is also a possibility that your details will be kept on file and we will get back to you once there is an opportunity to do a transaction. CFIE can’t guarantee you will receive an answer to your request.